Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Vinay Prasad, M.D., has left the FDA, less than three months into the role as director of the Center for Biologics Evaluation and Research, overseeing vaccines and cell and gene therapies. | Controversies,